NeuroSense Therapeutics Ltd.(NRSN)

Description: NeuroSense Therapeutics is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. NeuroSense believes that these diseases, which include ALS, Alzheimer's disease and Parkinson's disease, among others, represent one of the most significant unmet medical needs of our time, with limited effective therapeutic options available for patients. Due to the complexity of neurodegenerative diseases, NeuroSense's strategy is to develop combined therapies targeting multiple pathways associated with these diseases.

Keywords: Biotechnology Disease Biology Alzheimer's Disease Neuroscience Parkinson's Disease Neurodegenerative Diseases Neurodegeneration Senescence Gladstone Institutes

Home Page:

NRSN Technical Analysis

Building B
Herzliya, 4672562
Phone: 972 9 799 6183


Name Title
Mr. Alon Ben-Noon Co-Founder, CEO & Director
Mr. Or Eisenberg Chief Financial Officer
Ms. Hagit Binder VP of Operations
Ms. Yael Barak Head of QA & Compliance
Ms. Nedira Salzman-Frenkel Global Head of Bus. Devel.
Dr. Shiran Zimri Ph.D. Head of Scientific Program
Dr. Ferenc Tracik M.D. Chief Medical Officer
Ms. Diana Shtossel Head of Regulatory Affairs
Dr. Niva Russek-Blum Ph.D. Global Head of Discovery & IP Generator
Dr. Sharon Cohen Vered Ph.D. Global Head of CMC

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 2.3137
Price-to-Sales TTM: 0
IPO Date: 2021-12-09
Fiscal Year End: December
Full Time Employees: 11
Back to stocks